Please Wait a Moment
X

Articles

01May

CTS Implements HLA Class I and II Testing on the Gemini

01 May, 2019 | Return|

CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini on Monday, April 29th. As previously communicated, the Immucor assay and sample requirements are the same, and the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list are now available on our website.

 

 

 

 

Related

Reminder-Confirmatory Algorithm and Assay Changes Effective September 30, 2019

On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...

Read More >

Seasonal Monitoring for WNV to begin June 1, 2019

Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...

Read More >

FDA announces withdrawal of Guidance for ZIKV Testing

We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...

Read More >

Discontinue HIV-1 IFA Confirmatory Test

CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...

Read More >

2020 Annual CTS Survey

The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...

Read More >

Upcoming HCV Testing Algorithm Change

FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...

Read More >